The US Department of Health and Human Services (HHS), through the Centers for Medicare and Medicaid Services (CMS), has announced the selection of 15 new drugs covered under Medicare Part D for price negotiations.
In accordance with the Inflation Reduction Act (IRA), the negotiations with participating drug companies for these drugs will take place this year, and any negotiated prices will become effective in 2027.
Between November 2023 and October 2024, about 5.3 million people with Medicare Part D coverage used these drugs to treat a variety of conditions, such as cancer, type 2 diabetes, and asthma.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze